Goserelin: Uses, Mechanism, Evidence, and Side Effects

Anyone starting hormone therapy for prostate or breast cancer, or being treated for endometriosis, wants to know exactly what the drug does and how well it is understood. Goserelin is a long-studied synthetic hormone analogue with a well-documented approval history and a large body of clinical trial and safety reporting behind it.

Key takeaways

• Goserelin is a synthetic GnRH agonist sold under the brand name ZOLADEX.
• It is approved for prostate cancer, advanced breast cancer, endometriosis, and as an endometrial-thinning agent before ablation.
• More than 437 registered clinical trials have studied goserelin across these and related conditions.
• Reported adverse events most often involve disease progression, fatigue, and hormone-related effects like hot flush.
• FAERS reports reflect counts of submitted reports, not confirmed rates or causation.

What Goserelin Is

Goserelin is a synthetic decapeptide analogue of gonadotropin releasing hormone (GnRH). In its biodegradable formulation, it works by inhibiting the pituitary gland's secretion of gonadotropins, which in turn reduces the sex hormones that fuel certain cancers and hormone-sensitive conditions. Laboratory and animal studies have shown that goserelin can slow or shrink hormonally sensitive tumors, supporting its use in hormone-driven cancers (PubChem CID 5311128).

What Goserelin Is Approved For

Goserelin, marketed as ZOLADEX, carries several FDA-approved indications. It is used together with flutamide to manage locally confined prostate carcinoma (Stage T2b-T4), and on its own for palliative treatment of advanced prostate cancer. It is also approved for managing endometriosis, as an endometrial-thinning agent before endometrial ablation for dysfunctional uterine bleeding, and for palliative treatment of advanced breast cancer in pre- and perimenopausal women. The label does not carry a boxed warning.

What the Evidence Shows

Goserelin has been studied in more than 437 registered clinical trials spanning prostate cancer, breast cancer, and related hormone-dependent conditions. One completed Phase 1/2 trial examined goserelin combined with docetaxel and radiation therapy in men with high-risk localized prostate cancer. A completed Phase 2 trial evaluated goserelin alongside chemotherapy and radiation in locally advanced prostate cancer, while a Phase 3 trial has looked at its use in premenopausal women with hormone-responsive, HER2-negative, node-positive breast cancer.

Reported Side Effects

Safety reports submitted for goserelin most frequently describe outcomes related to underlying cancer progression, including death, malignant neoplasm progression, and metastases to bone, reflecting the advanced-stage populations who often receive this therapy. Fatigue and asthenia are also commonly reported, along with neutropenia, nausea, and hot flush, the latter consistent with goserelin's hormone-suppressing mechanism. These figures represent counts of submitted adverse event reports and do not establish incidence rates or prove that goserelin caused the event.